GlaxoSmithKline’s CEO Emma Walmsley has made great play of her company’s new approach to R&D under the leadership of its guru Hal Barron. After taking over in 2017 Walmsley is looking for a ...

GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also ...

GlaxoSmithKline has found a replacement for head of vaccines R&D Emmanuel Hanon, who left the company for a US biotech earlier this year, hiring Phil Dormitzer from ...

Harvey Jones has spotted signs of life in the GSK share price. Which is a relief after its recent troubles, so can the FTSE ...

Combining the science of the immune system and human genetics with advanced technologies is the cornerstone of R&D at GSK, underpinning a pipeline of 57 medicines and vaccines centred on ...

GSK plc (LON:GSK – Get Free Report)’s share price passed above its two hundred day moving average during trading on Thursday ...

Speaking at the CEO Times Summit in London, Walmsley highlights the U.K. pharmaceutical company's refocused R&D strategy, with investments concentrated in the U.K., U.S., and Europe. GSK ...

Hesham Abdullah, Senior Vice President, Global Head Oncology R&D, GSK, said: “This acquisition adds to GSK’s growing pipeline of targeted therapeutics for cancers originating in the ...

Farther Finance Advisors LLC decreased its holdings in shares of GSK plc (NYSE:GSK – Free Report) by 27.4% during the fourth ...

Under the BioVersys and GSK collaboration agreement, GSK is evaluating the early bactericidal activity (EBA) of alpibectir-ethionamide (AlpE) in a pulmonary tuberculosis (TB) trial, in combination ...